Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trans-resveratrol + hesperetin (tRES-HESP) is a dietary supplement consisting of the natural polyphenols trans-resveratrol and hesperetin. This combination acts as an inducer of glyoxalase 1 (Glo1), an enzyme that detoxifies methylglyoxal, a reactive dicarbonyl compound implicated in insulin resistance, vascular dysfunction, and neurodegeneration. The mechanism involves activation of the Nrf2 pathway, leading to increased Glo1 expression and reduced methylglyoxal levels. Clinical studies have shown that oral administration of tRES-HESP improves insulin sensitivity, glycemic control, vascular function, and reduces markers of inflammation in overweight or obese individuals with insulin resistance. Preclinical data also suggest neuroprotective effects against memory dysfunction and depression-like behavior via antioxidant, anti-apoptotic, and anti-inflammatory mechanisms[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trans-resveratrol + hesperetin.